Results 271 to 280 of about 32,848 (294)

Scrotal Ulcer After Intraperitoneal Hyperthermic Chemotherapy

Urology, 2007
Tumor cytoreduction combined with intraperitoneal hyperthermic chemotherapy has been shown to be an effective method to delay the progression of peritoneal carcinomatosis. We describe 2 cases of painful scrotal ulcer after tumor debulking and intraperitoneal infusion of mitomycin-C for treatment of metastatic abdominal malignancies.
Ardavan, Akhavan, Ming, Yin, Ronald, Benoit   +2 more
openaire   +2 more sources

Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors

Asian Journal of Endoscopic Surgery, 2020
AbstractIntroductionThe application of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal and appendix cancer at risk of peritoneal seeding is an appealing strategy to prevent peritoneal metastases. Here, we present the technical details and postoperative outcomes of laparoscopic HIPEC performed with prophylactic intent in three patients ...
Antonio Sommariva, Marco Tonello, Ottavia De Simoni, Andrea Barina, Carlo Riccardo Rossi, Pierluigi Pilati   +5 more
openaire   +2 more sources

[Hyperthermic intraperitoneal chemotherapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion.
H, Leebmann, P, Piso
openaire   +1 more source

Intraperitoneal hyperthermic chemotherapy in ovarian cancer

International Journal of Gynecological Cancer, 2005
We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB-IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles). Disease-free survival, overall survival, and side effects were compared with a control group of patients who ...
J, Gori, R, Castaño, M, Toziano, D, Häbich, J, Staringer, D G B, De Quirós, N, Felci   +6 more
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update

Hormone Molecular Biology and Clinical Investigation, 2020
Abstract In the treatment of advanced-stage epithelial ovarian cancer (EOC)-associated surgery and chemotherapy with intravenous platinum/taxane-based therapy most patients had early or late recurrence. Prevention of progression and recurrence is a major objective for the management of EOC.
Revaux, A., Carbonnel, M., Kanso, F., Naoura, I., Asmar, J., Kadhel, P., Ayoubi, J.-M.   +6 more
openaire   +3 more sources

Intraoperative fluid restriction in hyperthermic intraperitoneal chemotherapy

Journal of Surgical Research, 2018
Multiple studies highlight the importance of liberal fluid administration in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Over-resuscitation can delay recovery and wound healing. We report an intraoperative protocol that restricts fluid administration and minimizes morbidity.Retrospective analysis of 35 patients ...
Tariq Almerey, Emmanuel M. Gabriel, Klaus D. Torp, Sanjay P. Bagaria   +3 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Techniques

2015
Peritoneal carcinomatosis has long been considered a terminal condition and constitutes a difficult therapeutic challenge given the dismal prognosis associated with this entity and the debilitating effect it exerts on affected patients. Over the past decade, novel therapeutic approaches to peritoneal surface malignancies have emerged.
Salvatore Virzì, Domenico Rosario Iusco, Serena Bonomi, Antonio Grassi   +3 more
openaire   +1 more source

Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed

European Journal of Surgical Oncology (EJSO), 2016
CytoReductive Surgery and Hyperthermic IntraPEritoneal Chemotherapy (CRS-HIPEC) is now the preferred treatment of many peritoneal surface malignancies. In this retrospective study we aimed to analyze how several performance indicators changed during the first 100 CRS-HIPEC procedures in hospitals which recently introduced this treatment, and compare ...
Kuijpers, A. M., Hauptmann, M., Aalbers, A. G., Nienhuijs, S. W., de Hingh, I. H., Wiezer, M. J., van Ramshorst, B., van Ginkel, R. J., Havenga, K., Verwaal, V. J.   +9 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy: An Overview #412

Journal of Palliative Medicine, 2021
Ryan, Morgan, Sandy, Tun, Oliver S, Eng
openaire   +2 more sources

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BJA Education, 2021
S, Durnford, L, Boss, J, Bell
openaire   +2 more sources